Nuclear Medicine and Biology
Volume 37, Issue 3 , Pages 237-243 , April 2010

Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM

Received 8 October 2009 ,Revised 19 November 2009 ,Accepted 23 November 2009.

References 

  1. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225–239
  2. Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med. 2001;31(4):321–329
  3. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol. 1996;23(8):957–980
  4. Winkelmann DA, Bermke Y, Petering DH. Comparative properties of the antineoplastic agent, 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato) copper(II) and related chelates: linear free energy correlations. Bioinorg Chem. 1974;3(3):261–277
  5. Petering DH. The reaction of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato) copper(II) with thiols. Bioinorganic Chemistry. 1972;1:273–288
  6. Obata A, et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med. 2001;15(6):499–504
  7. Shelton ME, et al. Kinetics of copper-PTSM in isolated hearts: a novel tracer for measuring blood flow with positron emission tomography. J Nucl Med. 1989;30(11):1843–1847
  8. Maurer RI, et al. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem. 2002;45(7):1420–1431
  9. Wada K, et al. Cu-ATSM, an intracellular-accessible superoxide dismutase (SOD)-like copper complex: evaluation in an ischemia-reperfusion injury model. Biol Pharm Bull. 1994;17(5):701–704
  10. Wada K, Fujibayashi Y, Yokoyama A. Copper(II)[2,3-butanedionebis(N4-methylthiosemicarbazone)], a stable superoxide dismutase-like copper complex with high membrane penetrability. Arch Biochem Biophys. 1994;310(1):1–5
  11. Chan-Stier CH, Minkel D, Petering DH. Reactions of bis(thiosemicarbazonato) copper(II) complexes with tumor cells and mitochondria. Bioinorg Chem. 1976;6(3):203–217
  12. Dearling JL, et al. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure–activity relationships. J Biol Inorg Chem. 2002;7(3):249–259
  13. Holland JP, et al. In vitro kinetic studies on the mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals. Phys Med Biol. 2009;54(7):2103–2119
  14. Andersson BS, Aw TY, Jones DP. Mitochondrial transmembrane potential and pH gradient during anoxia. Am J Physiol. 1987;252(4 Pt 1):C349–C355
  15. Minkel DT, Saryan LA, Petering DH. Structure–function correlations in the reaction of bis(thiosemicarbazonato) copper(II) complexes with Ehrlich ascites tumor cells. Cancer Res. 1978;38(1):124–129
  16. Petering DH. Physico-chemical properties of the antitumor agent, 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato) copper (II). Bioinorganic Chemistry. 1972;1:255–271
  17. Lin SJ, Guarente L. Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr Opin Cell Biol. 2003;15(2):241–246
  18. Williamson DH, Lund P, Krebs HA. The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver. Biochem J. 1967;103(2):514–527
  19. Mintz S, Robin ED. Redox state of free nicotinamide-adenine nucleotides in the cytoplasm and mitochondria of alveolar macrophages. J Clin Invest. 1971;50(6):1181–1186
  20. Ballard FJ. Regulation of gluconeogenesis during exposure of young rats to hypoxic conditions. Biochem J. 1971;121(2):169–178
  21. O'Donoghue JA, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, PO2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61(5):1493–1502
  22. Fujibayashi Y, et al. Differential mechanism of retention of Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM) by brain and tumor: a novel radiopharmaceutical for positron emission tomography imaging. Ann Nucl Med. 1995;9(1):1–5
  23. Yuan H, et al. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2006;47(6):989–998
  24. Schroeder T, et al. Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. Cancer Res. 2005;65(12):5163–5171
  25. Burgman P, et al. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol. 2005;32(6):623–630
  26. Dehdashti F, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response—a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55(5):1233–1238
  27. Krohn KA, et al. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol. 2005;32(7):663–671

PII: S0969-8051(09)00284-4

doi: 10.1016/j.nucmedbio.2009.11.004

Nuclear Medicine and Biology
Volume 37, Issue 3 , Pages 237-243 , April 2010

Article Tools

* Image Usage & Resolution